AR095349A1 - Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa - Google Patents

Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa

Info

Publication number
AR095349A1
AR095349A1 ARP140101053A ARP140101053A AR095349A1 AR 095349 A1 AR095349 A1 AR 095349A1 AR P140101053 A ARP140101053 A AR P140101053A AR P140101053 A ARP140101053 A AR P140101053A AR 095349 A1 AR095349 A1 AR 095349A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
disease
alkyl
compound
pharmaceutically acceptable
Prior art date
Application number
ARP140101053A
Other languages
English (en)
Inventor
Dominguez Celia
Muoz Ignacio
Maillard Michel
D Vater Huw
E Jarvis Rebecca
A Luckhurst Christopher
W Burli Roland
Wishart Grant
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of AR095349A1 publication Critical patent/AR095349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1) o alguna de sus sales farmacéuticamente aceptable, caracterizado porque X es CR⁴ o N; R es seleccionado de entre C(O)NH(OH) y -N(OH)C(O)R⁷; R¹ es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R² es seleccionado de entre hidrógeno, alquilo C₁₋₄, halo, haloalquilo C₁₋₄ y nitrilo; R³ es seleccionado de entre -OR⁵, -NR⁵R⁶, alquilo opcionalmente sustituido, aralquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquenilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; R⁴ es seleccionado de entre hidrógeno, halo, alquilo C₁₋₄ o haloalquilo C₁₋₄; R⁵ y R⁶ son seleccionados independientemente de entre hidrógeno, alquilo C₁₋₄ opcionalmente sustituido, haloalquilo C₁₋₄ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, aralquilo opcionalmente sustituido y heteroaralquilo opcionalmente sustituido; o R⁵ y R⁶, junto con el átomo de nitrógeno al que están unidos, forman un heterocicloalquilo opcionalmente sustituido; y R⁷ es seleccionado de entre hidrógeno, alquilo C₁₋₄ y haloalquilo C₁₋₄.
ARP140101053A 2013-03-14 2014-03-14 Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa AR095349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785551P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095349A1 true AR095349A1 (es) 2015-10-07

Family

ID=51625124

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101053A AR095349A1 (es) 2013-03-14 2014-03-14 Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa

Country Status (4)

Country Link
US (1) US20160031863A1 (es)
AR (1) AR095349A1 (es)
TW (1) TW201514150A (es)
WO (1) WO2014159214A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6363164B2 (ja) 2013-03-14 2018-07-25 シーエイチディーアイ ファウンデーション，インコーポレーテッド ヒストンデアセチラーゼ阻害剤及びその組成物と使用方法
WO2014159218A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions
EP2968233A4 (en) 2013-03-14 2016-08-03 Chdi Foundation Inc HISTON DEACETYLASE HEMMER AND COMPOSITIONS AND METHOD FOR USE THEREOF
CA2951026A1 (en) 2014-06-02 2015-12-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3310350A4 (en) * 2015-06-16 2019-01-09 Spectrum Pharmaceuticals, Inc. COMBINED THERAPY USING BELINOSTAT AND PRALATREXATE FOR THE TREATMENT OF LYMPHOMAS
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN108147996B (zh) * 2018-01-12 2021-09-24 扬州大学 一种芳亚甲基双吡唑酯单钾盐的合成方法
CA3090764A1 (en) * 2018-01-30 2019-08-08 Pi Industries Ltd Novel anthranilamides, their use as insecticide and processes for preparing the same
CN109369554B (zh) * 2018-10-18 2022-06-17 中国药科大学 一种含有异羟肟酸的取代杂环类化合物及其制备方法和用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521244D0 (en) * 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof

Also Published As

Publication number Publication date
TW201514150A (zh) 2015-04-16
WO2014159214A1 (en) 2014-10-02
US20160031863A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
AR095349A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa
AR118340A2 (es) Mezclas fungicidas ternarias
AR094168A1 (es) Composiciones pesticidas y procesos relacionados con ellas
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR090862A1 (es) Compuestos de tetrazolinona y su uso para combatir plagas
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015006439A2 (pt) compostos de tetrazolinona e seu uso como pesticidas
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR093598A1 (es) Compuestos y sus metodos de empleo
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
RS54730B1 (sr) Inhibitori beta sekretaze
CR20150661A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
AR106604A1 (es) Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico
AR089815A1 (es) Compuestos que mejoran la actividad de los proteasomas
AR099581A1 (es) Compuestos de aminocarbonilcarbamato
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
AR097948A1 (es) Inhibidores de la proteasa de cisteína catepsina
DOP2016000009A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure